Svensson K, Carlsson A, Johansson A M, Arvidsson L E, Nilsson J L
J Neural Transm. 1986;65(1):29-38. doi: 10.1007/BF01249609.
N-alkylated and N,N-dialkylated cis-(+)-(1 S, 2 R)-5-methoxy-1-methyl-2-aminotetralins were tested for central dopamine receptor antagonism using in vivo biochemical and behavioral models in rats. The di-methyl analogue showed a profile similar to classical dopamine receptor antagonists. It produced a marked hypomotility including catalepsy and a pronounced increase in dopamine synthesis rate. This compound also displaced DiPr-5, 6-ADTN from striatal binding sites and antagonized the hyperactivity induced by the ligand. In contrast, the mono-propyl analogue increased locomotor activity and dopamine synthesis rate over a wide dose range. This compound failed to antagonize the hyperactivity induced by DiPr-5, 6-ADTN and to displace this in-vivo binding ligand. Thus, the mono-propyl analogue appears to lack postsynaptic dopamine receptor antagonistic properties; it seems to produce its effects via a selective dopamine autoreceptor antagonism. The di-ethyl and di-propyl, but not the dibutyl, analogues were also active in the models used. Whereas the di-ethyl compound shows a profile similar to classical dopamine receptor blockers, the di-propyl compound appears to act preferentially on autoreceptors.
使用大鼠体内生化和行为模型,对N-烷基化和N,N-二烷基化的顺式-(+)-(1S,2R)-5-甲氧基-1-甲基-2-氨基四氢萘进行了中枢多巴胺受体拮抗作用测试。二甲基类似物显示出与经典多巴胺受体拮抗剂相似的特征。它产生了明显的运动减少,包括僵住症,并使多巴胺合成速率显著增加。该化合物还从纹状体结合位点取代了DiPr-5,6-ADTN,并拮抗了由该配体诱导的多动。相比之下,单丙基类似物在很宽的剂量范围内增加了运动活性和多巴胺合成速率。该化合物未能拮抗DiPr-5,6-ADTN诱导的多动,也未能取代这种体内结合配体。因此,单丙基类似物似乎缺乏突触后多巴胺受体拮抗特性;它似乎是通过选择性多巴胺自身受体拮抗作用产生其效应的。二乙基和二丙基类似物(但二丁基类似物不)在所用模型中也具有活性。虽然二乙基化合物显示出与经典多巴胺受体阻滞剂相似的特征,但二丙基化合物似乎优先作用于自身受体。